Last reviewed · How we verify
Basiliximab Injection
Basiliximab Injection is a chimeric monoclonal antibody that binds to the alpha chain of the IL-2 receptor (CD25) on the surface of activated T lymphocytes.
Basiliximab Injection is a chimeric monoclonal antibody that binds to the alpha chain of the IL-2 receptor (CD25) on the surface of activated T lymphocytes. Used for Prevention of organ rejection in kidney transplant patients.
At a glance
| Generic name | Basiliximab Injection |
|---|---|
| Also known as | Simulect |
| Sponsor | Fort Worth Clinical Sciences Working Group |
| Drug class | Monoclonal antibody |
| Target | CD25 (IL-2 receptor alpha chain) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
By binding to CD25, basiliximab prevents IL-2 from interacting with its receptor, thereby inhibiting T cell activation and proliferation. This mechanism is thought to reduce the immune response and prevent organ rejection in transplant patients.
Approved indications
- Prevention of organ rejection in kidney transplant patients
Common side effects
- Headache
- Nausea
- Diarrhea
- Fatigue
- Infection
Key clinical trials
- Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients (PHASE2)
- Stem Cell Transplantation for Patients With Multiple Myeloma (PHASE1)
- Impact of the Microbiota on the Likelihood of Renal Graft Rejection
- Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients (PHASE2)
- Pediatric Induction Therapy in Kidney Transplantation
- Exploratory Regimen of Basiliximab for Treatment of Pulmonary Cytokine Storm in SARS-CoV-2 Hospitalized Adult Patients (PHASE2)
- Study of BEGEDINA® vs "Conventional Treatment" for Treating Steroid-Resistant Acute GvHD (PHASE3)
- Efficacy, Safety, Tolerability and Pharmacokinetic (PK) Study of GSK1070806 for the Prevention of Delayed Graft Function (DGF) in Adult Subjects After Renal Transplantation (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Basiliximab Injection CI brief — competitive landscape report
- Basiliximab Injection updates RSS · CI watch RSS
- Fort Worth Clinical Sciences Working Group portfolio CI